Navigation Links
Particle Sciences Expands Biopharmaceutical Development Infrastructure
Date:7/15/2014

BETHLEHEM, Pa., July 15, 2014 /PRNewswire/ -- Particle Sciences, Inc. has expanded its development capabilities to accommodate the increasing demand for biopharmaceutical formulation and analysis.  According to Robert Becker, Vice President Biopharmaceutical Sales and Business Development at Particle Sciences, "Our company has been working with biologics for some time, accumulating significant infrastructure and intellectual property.  We regularly work with biopharmaceuticals and vaccines ranging from therapeutic proteins, including monoclonal antibodies, to nucleotides, to vaccine antigens and immunomodulators.  Adding cell culture and extensive instrumentation to support the testing and characterizations of these biopharmaceuticals was planned for later this year but we've accelerated implementation to meet our client's needs."   With this most recent expansion, Particle Sciences can now run the full gambit of testing including, among others, ELISA, SDS-PAGE, Western blots, image analysis, HPLC, HPLC-MS, ligand-receptor binding assays, cellular proliferation, cytotoxicity and cellular activation assays.   

Mark Mitchnick, Particle Sciences' CEO added, "This expansion augments our existing formulation and sterile manufacturing offerings.  With our unique approach to biopharmaceutical formulation and the ability to quickly take our clients into the clinic, Particle Sciences anticipates becoming a leader in large molecule formulation and clinical trial supply."  The company sees a rapidly growing industrial need for these services as biopharmaceutical and biosimilar products become an increasingly important component to the health care products market. Particle Sciences' formulation portfolio enables the broader, more efficient development and application of biopharmaceuticals, and can differentiate products in the biosimilars field.

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  We also have an extensive history in government contracting alongside our clients.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com,  email info@particlesciences.com or contact us at (610) 861- 4701 for information.

Contact: Maureen Grieco
Maureen.grieco@particlesciences.com


'/>"/>
SOURCE Particle Sciences
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Shimadzu Introduces New Particle Size Analyzer for Measurement of Nanoparticles in Life Sciences and R&D
2. New magnetic behavior in nanoparticles could lead to even smaller digital memories
3. DNA motor walks along nanotube, transports tiny particle
4. Nanoparticles and their orbital positions
5. Researchers split water into hydrogen, oxygen using light, nanoparticles
6. IceCube Particle Detector in Antarctica Records High-energy Neutrinos
7. Scientists develop way to successfully give nanoparticle therapeutics orally
8. Pills of the future: Nanoparticles
9. Ultra-sensitive force sensing with a levitating nanoparticle
10. Magnetic nanoparticles could aid heat dissipation
11. BHR Pharma Engages Particle Sciences to Develop Nasal Progesterone for Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; ... Friday, February 24, 2017 a total of 10,672,750 common share ... per common share. Proceeds from the exercise of these warrants ... Treasury.   ... "We are grateful for this expression of confidence by our ...
(Date:2/27/2017)... and HAMILTON, Bermuda ... (NASDAQ: ADXS ) and ... companies focused on developing cancer immunotherapies, today announced ... develop a novel cancer immunotherapy agent using Advaxis, ... SELLAS, patented WT1 targeted heteroclitic peptide antigen mixture ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... can be safely completed in an ambulatory surgery center (ASC) with satisfactory clinical ... and previous two-year TDR studies. , Jake Lubinski, president of AxioMed, commented ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
Breaking Biology News(10 mins):